Dupont Merck Reluma Tc-99m can help detect malignancies in both fatty and dense breasts, study shows.
This article was originally published in The Gray Sheet
Executive Summary
DUPONT MERCK RELUMA Tc-99m MARKER 70% ACCURATE IN DETECTING MALIGNANCY in a study group of women with nonpalpable suspected breast cancer found by mammography, Janet Baum, MD, Beth Israel Deaconess Medical Center, Boston, reported Dec. 2 at the Radiological Society of North America's annual meeting in Chicago. In the patient group, the test had an 82% negative predictive value. For breast masses detected through palpation, Tc-99m sestamibi, which Dupont Merck plans to market under the name Reluma, correctly identified 77% of the malignancies and had an 86% negative predictive value. All diagnoses were confirmed through excisional biopsy or mastectomy.